Stock listing

Lang & Schwarz:A2JRKN Ascletis Pharma, Inc. Aktie

German listing (Lang & Schwarz) of Ascletis Pharma, Inc. · home listing HKEX:1672

Follow Ascletis Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · HKEX:1672

$5.85 HKD +0.06 (+1.1%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:1672

Past year -40.2% · daily closes, Oct 16, 2025 – Oct 16, 2026, adjusted for splits
Day range
$5.73 – $6.24 HKDOct 16, 2026
Volume
3.42M sharesOct 16, 2026
Market value
$6.14B HKDAt the close on Oct 16, 2026 · price × 1.05B shares outstanding
52-week range
$5.40 – $19.86 HKDLowest and highest trades, Oct 17, 2025 – Oct 16, 2026
Ascletis Pharma, Inc. logo
Ticker
Lang & Schwarz:A2JRKN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity

Oct 20, 2026

Next Day Disclosure Return

Oct 16, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

Oct 6, 2026

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

Oct 2, 2026

Interim Report 2026

Sep 29, 2026

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

Sep 29, 2026

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Sep 8, 2026

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

Sep 7, 2026

Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management

Aug 30, 2026

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

Aug 10, 2026

All Ascletis Pharma, Inc. news

Decks

Ascletis Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
43 in the last 12 months · 69 in all · newest Oct 20, 2026 · oldest 2025
Decks
4 decks · latest August 2026

Where Ascletis Pharma, Inc. is listed

ListingExchangeCountryCurrency
HKEX:1672 歌禮製藥 · Home listingHKEXHong KongHKD
Tradegate:2VJTradegateGermanyEUR
OTC:ASCLFOTCUnited StatesUSD
LS Exchange:A2JRKNLS ExchangeGermanyEUR
gettex:2VJgettexGermanyEUR
Lang & Schwarz:A2JRKN · This pageLang & SchwarzGermanyEUR
Frankfurt:2VJFrankfurtGermanyEUR
Dusseldorf:2VJDusseldorfGermanyEUR
Munich:2VJMunichGermanyEUR
Stuttgart:2VJStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Ascletis Pharma, Inc.